Identification of resistance mechanisms to EGFR treatment in the real world using a clinicogenomic database Published April 2018 Citation Singal, G, Li, G, Agarwala, V, Kaushik, G, O’Connell, C, Alpha-CobbG, Caron, T, Bourque, D, Guria, A, Frank, S, Frampton, G, Carson, K, Abernethy, A.P., Miller, V.A. . AACR Annual Meeting. . https://4076230.fs1.hubspotusercontent-na1.net/hubfs/4076230/flatiron-com-pdf/AACR-2018-FH-FMI-CGDB-Poster-180411.pdf Authors: Sources:American Association for Cancer Research Annual Meeting Share Posted inPublicationsDrug discovery More publicationsASCO Annual MeetingMay 2026Real-world biomarker testing rates, targeted therapy use, and clinical outcomes in patients with advanced gastric or GEJ cancer in the United StatesDamato L, Liao NS, Bryan J, Hankinson EA, Castellanos E.Publication summaryPublicationsPrecision medicineGastric/Esophageal cancerASCO Annual MeetingMay 2026From plenary to practice: A large language model (LLM)-based thematic analysis of landmark clinical trial discussions and factors influencing their real-world adoptionCohen AB, Williams T, Aggarwal C, et al.Publication summaryPublicationsMachine learningArtificial intelligenceASCO Annual MeetingMay 2026Comparison of real-world overall survival between atezolizumab- and durvalumab-containing first- line induction and maintenance regimens in extensive-stage small cell lung cancerGanti AK, Snider J, Yan J, et al.Publication summaryPublicationsComparative effectivenessSmall cell lung cancer